Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Integrins and dystroglycan are the two primary classes of transmembrane receptors that anchor muscle fibers and nerve cells to the extracellular matrix (ECM) (UniProt P55051, Q13683). In skeletal muscle, the alpha7beta1 integrin and the dystroglycan complex (comprising alpha and beta subunits) serve as critical mechanical links between the laminin-rich basement membrane and the internal cytoskeleton (Michele & Campbell, 2003). These receptors are essential for maintaining the structural integrity of the sarcolemma during muscle contraction and for mediating signal transduction pathways that regulate cell survival and differentiation (Belkin & Burridge, 2000). Mutations or deficiencies in these proteins, or the enzymes responsible for their post-translational modification (particularly for dystroglycan), lead to various forms of muscular dystrophy, such as Duchenne and congenital muscular dystrophies, as well as neurological disorders like Walker-Warburg syndrome (UniProt P55051). In nerve cells, these molecules are involved in the formation of the neuromuscular junction and the maintenance of the blood-brain barrier. Therapeutic strategies often focus on upregulating integrin expression to compensate for the loss of the dystrophin-glycoprotein complex or restoring proper glycosylation of alpha-dystroglycan to maintain muscle stability (Rooney et al., 2012).
Restoration of the mechanical linkage between the extracellular matrix and the intracellular cytoskeleton to prevent sarcolemmal rupture and muscle fiber degeneration.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Integrins and dystroglycan on muscle fibers and nerve cells.